<DOC>
	<DOC>NCT02980874</DOC>
	<brief_summary>This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.</brief_summary>
	<brief_title>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>Has a clinical diagnosis of RVO in the study eye Has a CST of ≥ 300 µm in the study eye Has an ETDRS BCVA score of ≥ 5 letters read and ≤ 70 letters read in the study eye; Is naïve to local pharmacologic treatment for RVO in the study eye; Any active ocular disease or infection in the study eye other than RVO Intraocular pressure &gt; 22mmHg or uncontrolled glaucoma in study eye Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study Any evidence of neovascularization in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>RVO</keyword>
	<keyword>ME</keyword>
	<keyword>Central Subfield Thickness</keyword>
	<keyword>OCT</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Cystoid Macular Edema</keyword>
	<keyword>Subretinal Fluid</keyword>
	<keyword>Eylea</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>Suprachoroidal</keyword>
</DOC>